1. An optical disc drive apparatus, comprising:
a box-shaped cabinet having an opening in a front face;
a frame provided in said cabinet and having a sidewall; and
a disc tray supported by said frame; wherein
said optical disc drive apparatus is structured such that said disc tray can freely slide between a disc-loaded position at which a disc recording medium is held and allowed to rotate in said cabinet and a disc-removable position at which the disc tray partially comes out in a forward direction from said opening so as to allow loading and removing of the disc recording medium, by engagement of a supporting portion provided in said sidewall of said frame to a supported portion provided at a side edge of said disc tray,
said supporting portion includes a guide rib formed protruding from an inner wall surface of said sidewall toward a center portion of the disc drive apparatus, and a plurality of guide protrusions formed protruding upward from said guide rib in a front-to-rear direction of said guide rib,
said supported portion has a guide groove slidably engaging to said plurality of guide protrusions on a lower face side of said disc tray,
a guide protrusion positioned at forefront among said plurality of guide protrusions is structured so as to come in surface-contact with a wall surface implementing said guide groove, and
a root portion of said guide protrusion has a width increasing solely toward the center portion of the disc drive apparatus with respect to its tip end portion.
2. An optical disc drive apparatus, comprising:
a box-shaped cabinet having an opening in a front face;
a frame provided in said cabinet and having a sidewall; and
a disc tray supported by said frame; wherein
said optical disc drive apparatus is structured such that said disc tray can freely slide between a disc-loaded position at which a disc recording medium is held and allowed to rotate in said cabinet and a disc-removable position at which the disc tray partially comes out in a forward direction from said opening so as to allow loading and removing of the disc recording medium, by engagement of a supporting portion provided in said sidewall of said frame to a supported portion provided at a side edge of said disc tray,
said supporting portion includes a guide rib formed protruding from an inner wall surface of said sidewall toward a center portion of the disc drive apparatus, and a plurality of guide protrusions formed protruding upward from said guide rib in a front-to-rear direction of said guide rib,
said supported portion has a guide groove slidably engaging to said plurality of guide protrusions on a lower face side of said disc tray, and
a guide protrusion positioned at forefront among said plurality of guide protrusions is structured so as to come in surface-contact with a wall surface implementing said guide groove.
3. The optical disc drive apparatus according to claim 2, wherein
said guide protrusion positioned at the forefront has a width larger in its root portion than in its tip end portion.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating a subject having a NO-related condition, the method comprising:
recognizing that the subject has the NO-related condition; and
administering to the subject a therapeutically effective amount of a nanocrystalline metal-containing material.
2. The method of claim 1, wherein the nanocrystalline metal-containing material comprises a nanocrystalline silver-containing material.
3. The method of claim 2, wherein the nanocrystalline silver-containing material is an atomically disordered, crystalline material.
4. The method of claim 1, wherein the nanocrystalline metal-containing material forms a NO-containing complex.
5. The method of claim 1, wherein, prior to being administered to the subject, the nanocrystalline metal-containing material is in contact with a solution.
6. The method of claim 5, wherein the solution comprises a body fluid.
7. The method of claim 1, wherein the nanocrystalline metal-containing material is injected into the subject, topically applied to the subject, ingested by the subject or inhaled by the subject.
8. The method of claim 1, wherein the nanocrystalline metal-containing material is administered in the form of a tape, a pill, a capsule, a tablet, a lozenge or a suppository.
9. The method of claim 1, wherein the nanocrystalline metal-containing material is administered as a powder.
10. The method of claim 1, wherein the nanocrystalline metal-containing material is administered in the form of a pharmaceutical composition that comprises the nanocrystalline metal-containing material and at least one pharmaceutically acceptable carrier.
11. The method of claim 1, wherein the nanocrystalline metal-containing material is reacted with a nitrogen-containing species to form a NO-containing complex.
12. A method of treating a subject having a NO-related condition, the method comprising:
recognizing that the subject has a NO-related condition; and
administering to the subject a therapeutically effective amount of a source of solution phase neutral silver.
13. The method of claim 12, further comprising reacting the solution phase neutral silver with a nitrogen-containing species to form NO.
14. The method of claim 13, wherein the NO forms a NO-containing complex.
15. The method of claim 12, wherein the neutral silver is present in an aqueous solution.
16. A method of treating a subject having a NO-related condition, the method comprising:
recognizing that the subject has a NO-related condition; and
administering to the subject a therapeutically effective amount of a NO-containing complex.
17. The method of claim 16, wherein the NO-containing complex is in contact with a solution.
18. The method of claim 17, wherein the solution comprises a body fluid.
19. A method of treating a subject susceptible to having a NO-related condition, the method comprising:
recognizing that the subject is susceptible to having a NO-related condition; and
administering to the subject a therapeutically effective amount of a nanocrystalline metal-containing material.
20. The method of claim 19, wherein the nanocrystalline metal-containing material comprises a nanocrystalline silver-containing material.
21. The method of claim 20, wherein the nanocrystalline silver-containing material is an atomically disordered, crystalline material.
22. The method of claim 19, wherein the nanocrystalline metal-containing material forms a NO-containing complex.
23. The method of claim 19, wherein, prior to being administered to the subject, the nanocrystalline metal-containing material is in contact with a solution.
24. The method of claim 23, wherein the solution comprises a body fluid.
25. The method of claim 23, wherein the nanocrystalline metal-containing material is injected into the subject, topically applied to the subject, ingested by the subject or inhaled by the subject.
26. The method of claim 19, wherein the nanocrystalline metal-containing material is administered as a powder.
27. The method of claim 19, wherein the nanocrystalline metal-containing material is reacted with a nitrogen-containing species to form a NO-containing complex.
28. A method of treating a subject susceptible to having a NO-related condition, the method comprising:
recognizing that the subject is susceptible to having the NO-related condition; and
administering to the subject a therapeutically effective amount of a source of solution phase neutral silver.
29. The method of claim 28, further comprising reacting the solution phase neutral silver with a nitrogen-containing species to form NO.
30. The method of claim 29, wherein the NO forms a NO-containing complex.
31. The method of claim 28, wherein the neutral silver is present in an aqueous solution.
32. A method of treating a subject susceptible to having a NO-related condition, the method comprising:
recognizing that the subject is susceptible to having the NO-related condition; and
administering to the subject a therapeutically effective amount of a NO-containing complex.
33. The method of claim 32, wherein the NO-containing complex is in contact with a solution.
34. The method of claim 33, wherein the solution comprises a body fluid.
35-53. (canceled)